Cadent Therapeutics, Inc.

Aclaris Therapeutics, Inc.

Novartis Ag

Pfizer Corporation

Optuminsight, Inc.

Other

Ingenix, Inc.

Luc Therapeutics, Inc.

Optum, Inc.

Adaris Therapeutics, Inc.

David R Anderson

Robert A Volkmann

Frank S Menniti

Christopher Fanger

Eric Jon Jacobsen

James Robert Blinn

Susan Landis Hockerman

Christoph Martin Dehnhardt

Joseph Walter Strohbach

Eddine Saiah

Horng-Chih Huang

Akshay Patny

David Hepworth

Kevin Joseph Curran

Christoph Wolfgang Zapf

Xiaolun Wang

Nikolaos Papaioannou

Arthur Lee

Stephen Wayne Wright

Frank Eldridge Lovering

Katherine Lin Lee

John David Trzupek

Joel A Goldberg

Michael Dennis Lowe

Richard Vargas

Seungil Han

Lori Krim Gavrin

Betsy Susan Pierce

Mark Edward Bunnage

John Paul Mathias

Paramita Mukherjee

Jean Rawlings

Gregg F Keaney

Yuelian Xu

Timothy Piser

Carl Kraus

Andrew Paris

Steven C Leiser

Richard Heier

Sam Malekiani

John Robert Springer

Christopher A Hane

Paul S Changelian

Gary A Decrescenzo

Frank Kostka

Peter M Gallagher

Canxin Xu

Frank J Kostka

The present disclosure provides deuterated pyridinone-pyridinyl compounds and compositions useful in the treatment of p38 MAP Kinase mediated having the structures of Formula (I); wherein the A, B, and R groups are as defined in the detailed description. Methods of inhibition of p38 MAP Kinase activity in a human or animal subject are also provided.

Deuterated MK2 pathway inhibitors and methods of using the same

Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.

NMDA receptor modulators and uses thereof

Disclosed herein are arylpyridinone compounds and compositions useful in the treatment of ITK mediated diseases, such as inflammation, having the structures of Formulas (I)-(IV): wherein the R groups, m, n, and X are as defined in the detailed description. Methods of inhibition of ITK activity in a human or animal subject are also provided.

Pyrrolopyrimidine ITK inhibitors

The present invention relates to new pyrrolopyridine compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibition of JAK1 and JAK3 kinase activity in a human or animal subject are also provided for the treatment diseases such as pruritus, alopecia, androgenetic alopecia, alopecia areata, vitiligo and psoriasis.

Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same

Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. In an embodiment, a pharmaceutical composition can be in a liquid dosage form and can comprise a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof as an adjuvant and a therapeutic agent. In another embodiment, a method of adjuvant treating a disorder or condition can comprising administering the pharmaceutical composition to a patient.

Bicyclic-fused heteroaryl or aryl compounds

Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated modulate the NMDA receptor.

Heteroaromatic NMDA receptor modulators and uses thereof

Compounds that selectively negatively modulate NMDA receptors containing an NR1/NR2B subunit, pharmaceutical compositions comprising the compounds, and methods of treating a disease using the compounds are disclosed.

Selective octahydro-cyclopenta[c]pyrrole negative modulators of NR2B

The present disclosure relates to N-alkylaryl-5-oxyaryl-octadihydrocyclopent[c]pyrrole negative allosteric modulators of NR2B receptors useful in the treatment of neurological diseases having the Formula I: where R, R, L, L, X, Y, and Y' are described therein.

N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[C]pyrrole negative allosteric modulators of NR2B

Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Thienopyrimidinone NMDA receptor modulators and uses thereof

Provided is 5-(3-chloro-4-fluorophenyl)-7-cyclopropyl-3-(2-(3-fluoro-3-methylazetidin-1-yl)-2-oxoethyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one and pharmaceutically acceptable salts thereof, and their uses in the treatment of psychiatric, neurological, and neurodevelopmental disorders, as well as diseases of the nervous system.

Disclosed herein, in part, are methods of treating neurological disorders, e.g., schizophrenia and major depressive disorder, comprising administering an effective amount of a disclosed heterocyclic compound. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.

Growing community of inventors

Salem, CT, United States of America

David R Anderson